March 14, 2025 – Nusano’s radioisotope production platform is profiled in a Salt Lake City Business Journal article:
Chris Lowe, company CEO, said the origin of Nusano was “to address the underlying problems that have plagued national research labs and countries’ programs for decades — the limitations of isotope production and the basic separation properties of the physics involved with isotopes.”
…Isotopes “don’t really care what they’re used for,” Lowe said with a smile. “They are the foundation of some very breakthrough treatments in the cancer field, specifically radioligand therapy that can help diagnose, monitor and treat various cancers. There are a couple of hundred drugs currently under clinical research for cancer, and our role is to be able to enable those researchers to have 40 to 50 different isotopes to choose from, rather than just two or three as has been the case. What started as a challenge for us nearly a decade ago has turned into a tremendous opportunity to impact mankind in a variety of ways over the coming years.”
Read full article at slenterprise.com.
